http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2654596-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb311aa36169344465a81056a3ea2481 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-320008 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-3205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-116 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate | 2013-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de7edc55e3ef3e26358e0007a77a6cee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec70bd61d48f12f641de9d1c89b30102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd220b7424ce07d9650f3adbe61428bb |
| publicationDate | 2018-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2654596-C2 |
| titleOfInvention | Compositions comprising cocktails of antibacterial phages and uses thereof |
| abstract | FIELD: medicine. n SUBSTANCE: present invention relates to the field of phage therapy and to a composition and use thereof. Present composition comprises: a first and second purified bacteriophage strains, each of said strains having a genome characterized by at least 99% sequence identity to the corresponding nucleic acid sequence, selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, showing antibacterial activity against Staphylococcus aureus; third and fourth purified bacteriophage strains having a genome characterized by at least 99% sequence identity to the nucleic acid sequences SEQ ID NO:3 and SEQ ID NO:4, respectively, showing antibacterial activity against Pseudomonas aeruginosa; and a fifth purified bacteriophage strain having a genome characterized by at least 99% sequence identity to the nucleic acid sequence SEQ ID NO:5 showing antibacterial activity against Acinetobacter baumannii. Each of said first, second, fourth and fifth bacteriophage strains is present in the composition in an amount corresponding to about 10 times that of the third bacteriophage strain. Present method comprises administering to a subject a therapeutically effective amount of said composition. n EFFECT: inventions can be used for the treatment and control of bacterial infections, caused by one or more of Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii, in particular diabetic foot infections. n 25 cl, 14 dwg, 1 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2794585-C2 |
| priorityDate | 2012-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 410.